US FDA approves Verona Pharma's Ohtuvayre (ensifentrine) as a novel COPD treatment, first in 20 years.
The US FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as a treatment for chronic obstructive pulmonary disease (COPD), making it the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in over 20 years. Ohtuvayre is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), which combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. This approval marks a significant milestone for Verona Pharma and offers a new inhaled non-steroidal treatment option for the millions of COPD patients worldwide.
June 26, 2024
16 Articles